June 11, 2025 02:21 PM EDT

House appropriators call for FDA tweaks on accelerated approvals, biosimilars

Zachary Brennan

Senior Editor

House appropriators are calling on the FDA to boost biosimilar access and better align its accelerated approval pathway across its drug and biologics centers. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

House appropriators call for FDA tweaks on accelerated approvals, biosimilars

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Bristol Myers gets a key strategist with 'Team Shibs'; Idorsia to change CEOs after it 'hit a reset button'

Rein Therapeutics study on clinical hold; Beam updates sickle cell therapy data

Another round of consolidation is coming, FDA commissioner tells staff

AstraZeneca inks AI drug R&D deal with Chinese pharma for $110M upfront

With HIV prevention under attack, how might Gilead’s new PrEP injection fare?

McKesson leads the charge in revolutionizing precision oncology in community practices

House ap­pro­pri­a­tors call for FDA tweaks on ac­cel­er­at­ed ap­provals, biosim­i­lars

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Bris­tol My­ers gets a key strate­gist with 'Team Shib­s'; Idor­sia to change CEOs af­ter it 'hit a re­set but­ton'

Rein Ther­a­peu­tics study on clin­i­cal hold; Beam up­dates sick­le cell ther­a­py da­ta

An­oth­er round of con­sol­i­da­tion is com­ing, FDA com­mis­sion­er tells staff

As­traZeneca inks AI drug R&D deal with Chi­nese phar­ma for $110M up­front

With HIV pre­ven­tion un­der at­tack, how might Gilead’s new PrEP in­jec­tion fare?

McKesson leads the charge in rev­o­lu­tion­iz­ing pre­ci­sion on­col­o­gy in com­mu­ni­ty prac­tices

House appropriators call for FDA tweaks on accelerated approvals, biosimilars

Bristol Myers gets a key strategist with 'Team Shibs'; Idorsia to change CEOs after it 'hit a reset button'

Rein Therapeutics study on clinical hold; Beam updates sickle cell therapy data

Another round of consolidation is coming, FDA commissioner tells staff

AstraZeneca inks AI drug R&D deal with Chinese pharma for $110M upfront

With HIV prevention under attack, how might Gilead’s new PrEP injection fare?

McKesson leads the charge in revolutionizing precision oncology in community practices